Theragnostics inks AstraZeneca agreement

AuntMinnie.com staff writers
Sep 4, 2019

Molecular radiotherapy developer Theragnostics said it has signed an intellectual property agreement with AstraZeneca.

The agreement allows Theragnostics to develop radiotherapy based on radionuclide-labeled poly (ADP-ribose) polymerase (PARP) inhibitors, a class of oncology drugs that block the PARP enzyme, which cancer cells use in response to DNA damage.
Latest in Radiation Oncology/Therapy
Prostate Imaging
What is the best timing for PET scans after radiotherapy?
March 28, 2025
Radiation Therapy Suite 400
ASTRO vice chair highlights momentum for ROCR Act
March 19, 2025
Trends
Consolidation reigns in radiation oncology
March 7, 2025
Breast Cancer3 400
ASTRO: Shorter radiation course safe for breast reconstruction
October 2, 2024
Related Stories
2021 09 14 23 49 7847 Business Handshake 400
Molecular Imaging
Theragnostics enters licensing deal with AAA for Ga-68 PET
2020 07 28 23 23 5650 Business Hands Cooperation 400
Molecular Imaging
Theragnostics names two new board directors
2017 09 14 23 05 1167 Cancer Cell 400
Molecular Imaging
Theragnostics, German hospital to study THG-008 for PET
2018 08 28 18 59 9066 Artificial Intelligence Ai 400
AI
AstraZeneca, Qure.ai partner for lung cancer diagnosis
More in Radiation Oncology/Therapy
What is the best timing for PET scans after radiotherapy?
By Will Morton
Men should have prostate-specific membrane antigen PET scans about eight months after undergoing external beam radiotherapy for prostate cancer.
March 28, 2025
Prostate Imaging
ASTRO vice chair highlights momentum for ROCR Act
By Amerigo Allegretto
Chris Corso, MD, PhD, from ASTRO discusses why the ROCR Act is needed to stabilize reimbursement for radiation oncologists in the U.S.
March 19, 2025
Radiation Therapy Suite 400
Consolidation reigns in radiation oncology
By Will Morton
Solo practices in radiation oncology dropped significantly between 2015 and 2023 while the number of large practices increased by more than half.
March 7, 2025
Trends
ASTRO: Shorter radiation course safe for breast reconstruction
By Amerigo Allegretto
Research presented at the ASTRO annual meeting shows that a shorter course of postmastectomy radiation combined with breast reconstruction is safe.
October 2, 2024
Breast Cancer3 400
ASTRO: Timing key to adding immunotherapy to chemoradiation
By Amerigo Allegretto
Timing may be key when adding immunotherapy to chemoradiation for lung cancer treatment.
October 1, 2024
Lung Cancer
ASTRO: Black patients voice distrust in medical research
By Will Morton
Spiritual beliefs and a distrust of clinical research may partly explain why Black patients choose not to participate in cancer trials.
September 30, 2024
Black Patient
ASTRO: IMRT and proton therapy equally effective for prostate cancer
By Will Morton
Intensity-modulated radiation therapy (IMRT) and proton therapy offer equally high quality of life and tumor control for people with prostate cancer.
September 30, 2024
Prostate Imaging
ASTRO: Lu-177 dotatate shows promise for treating meningioma patients
By Kate Madden Yee
A radiopharmaceutical therapy that lengthens progression-free survival for patients with neuroendocrine cancer could help treat meningioma sufferers.
September 30, 2024
Brain
ASTRO: Brain cancer patients treated by radiation recoup cognitive function
By Kate Madden Yee
Patients with brain metastases who experience cognitive side effects after radiation therapy appear to eventually regain cognitive function.
September 30, 2024
Brain Puzzle Dementia
Bone marrow disorders associated with SARs in Lutathera patients
By Will Morton
Pretreatment bone marrow disorders may predict which patients are at risk for severe adverse reactions (SARs) when treated with lutetium-177 DOTATATE.
July 15, 2024
2024 07 11 Sa Rs Patients Lu 177 Dotatate Voter
The rise of theranostics: Part 5 -- Advice from center administrators
By Liz Carey
Want to launch theranostics at your hospital and cancer center? An SNMMI 2024 session provided key planning steps.
July 12, 2024
Nuclear medicine technologist and theranostics practice administrator Dmitry Beyder (left) and Vikas Prasad, MD, PhD (right), lead the theranostics center at Barnes-Jewish Hospital/Washington University in Saint Louis, MO. Image courtesy of Washington University.
Risk factor for blood disorders identified in PRRT patients
By Will Morton
Researchers have identified a risk factor that may be involved in potentially fatal blood disorders in patients undergoing peptide receptor radionuclide therapy (PRRT).
July 12, 2024
Cytopenia
Page 1 of 462
Next Page